GlassScriptPhysician profile
Randi D Bragg
NPI 1700420031
$4,790.39
in general payments reported to CMS, 2019-2025
31 companies · $1,339 in 2025
The $1,339 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $688 · 2022: $1,017 · 2023: $941 · 2024: $805 · 2025: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,001 · Education: $84.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,000.99 |
| Education | $84.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,152.72 | 2022-2025 | |
| Glaxosmithkline, LLC. | $377.11 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $339.88 | 2022-2025 | Rexulti, Nuedexta |
| Supernus Pharmaceuticals, INC. | $283.73 | 2021-2023 | Qelbree |
| Lilly USA, LLC | $256.58 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Corium, LLC | $224.15 | 2021-2024 | Azstarys |
| Axsome Therapeutics, INC. | $209.18 | 2023-2025 | Auvelity |
| Corcept Therapeutics | $184.34 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $183.02 | 2021-2023 | Glassia |
| Astrazeneca Pharmaceuticals LP | $173.78 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $169.17 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $156.93 | 2025 | Fanapt, Hetlioz |
| Bayer Healthcare Pharmaceuticals INC. | $151.23 | 2022-2025 | |
| Gilead Sciences, INC. | $151.21 | 2023-2025 | |
| Exact Sciences Corporation | $145.06 | 2023-2024 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $116.41 | 2022-2025 | |
| Avanir Pharmaceuticals, INC. | $69.64 | 2022 | |
| Organon LLC | $60.29 | 2022-2023 | Nexplanon |
| Amgen INC. | $59.10 | 2022-2024 | Repatha, Otezla |
| Alkermes, INC. | $50.96 | 2022-2023 | Aristada, Lybalvi |
| Biogen, INC. | $49.63 | 2025 | Zurzuvae |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.89 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $40.57 | 2022 | |
| Lundbeck LLC | $33.53 | 2022-2023 | Rexulti |
| Tandem Diabetes Care, INC. | $19.70 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Genentech USA, INC. | $15.87 | 2021 | |
| Neos Therapeutics, LP | $15.72 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.70 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $14.17 | 2022 | |
| Astellas Pharma US INC | $13.59 | 2025 | Veozah |
| Sanofi Pasteur INC. | $13.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randi Bragg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.